FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc . (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek ® Guava ® Muse ® cell analyzer, creating a next-generation instrument called the Cytek ® Muse ® Micro . The Muse Micro cell analyzer is an affordable... Read More

FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc . (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9%... Read More

FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results,... Read More

FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 12 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Participating on Tuesday, February 11 and Wednesday, February 12, 2025 Raymond James 46 th Annual... Read More

FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek’s 2023 revenue of $193.0 million. This included a negative foreign... Read More

FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Cytek management is scheduled to present on Thursday, January 16 th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live... Read More

FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024.... Read More

FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36 th Annual Healthcare Conference in New York, NY. Cytek management is scheduled to participate in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Interested... Read More

FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough , a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and... Read More

FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system . This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug delivery, cell therapy, disease diagnostics, circulating tumor... Read More

FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second... Read More

FREMONT, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences in November. Guggenheim Inaugural Healthcare Conference in Boston, MA Fireside chat on Monday, November 11, 2024, at 11:00 a.m. Eastern Time UBS Global Healthcare Conference in Rancho Palos Verdes, CA... Read More

FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business... Read More

FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year’s premier clinical industry events across the globe. Continuing its commitment to advancing cell analysis, Cytek will spotlight its Full Spectrum Profiling™ (FSP™) technology at the European Society for Clinical Cell Analysis (ESCCA) 2024 Conference in September and the 39th International... Read More

FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more... Read More

FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification. This certification encompasses the design, development, manufacturing, and distribution of reagents and accessories, highlighting the company's adherence to rigorous quality standards.... Read More

FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Genomic Medicine Summit in Dana Point, CA Panel discussion: Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Wells Fargo... Read More

FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the... Read More

FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has developed a revolutionary tool to automate panel design. The company has expanded the capabilities of the Panel Builder tool within its Cytek ® Cloud digital ecosystem with the addition of SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes. Optimized for... Read More

FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2024 after market close on Tuesday, August 6, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business... Read More

FREMONT, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program... Read More

FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 45 th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 12 th at 9:20 a.m. Eastern Time / 6:20 a.m. Pacific Time. Interested... Read More

FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products Administration (NMPA) approval for clinical diagnostic use on the Cytek ® Northern Lights™-Clinical (NL-CLC™) cell analysis systems in hospitals, laboratories and clinics across China. This is the first clinical... Read More

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora ™ and Cytek Northern Lights ™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular... Read More

FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11%... Read More

FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™) technology, designed for streamlining workflows, expediting discoveries, and enhancing efficiency, will be prominently... Read More

FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8 th , 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business... Read More

Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and... Read More

FREMONT, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company's manufacturing capacity to meet the growing worldwide demand for... Read More

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14%... Read More

FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 11 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah Participating on Tuesday, February 13 th and Wednesday, February 14 th Raymond James 45 th Annual... Read More

FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28 th , 2024. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its... Read More

FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community. Cytek’s collaboration serves as a testament to the substantial impact of... Read More

FREMONT, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023. Cytek expects its full year revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million, provided on November 9, 2023. The... Read More

FREMONT, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. CEO Dr. Wenbin Jiang is scheduled to present and participate in a Q&A session on Thursday, January 11, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time.... Read More

FREMONT, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the introduction of the Cytek Orion™ reagent cocktail preparation system . Cytek’s new automated reagent cocktailing technology simplifies and accelerates laboratory workflow,... Read More

FREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 35 th Annual Healthcare Conference in New York, New York. Cytek management is scheduled to participate in a fireside chat on Tuesday, November 28 th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. Interested... Read More

FREMONT, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that its Cytek ® Aurora™ CS system has been selected as the “Cell Sorting Product of the Year” in the third annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough , a leading independent market intelligence organization that evaluates and... Read More

FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Total revenue was $48.0 million, representing 19% growth over the third quarter of 2022 Total revenue on a non-GAAP constant currency basis was $47.7 million... Read More

FREMONT, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7 th , 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business... Read More

FREMONT, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has received EN ISO 13485:2016 Quality Management System (QMS) certification. The certification applies to Cytek’s headquarters and manufacturing operations in Fremont, California for the design, development, manufacturing, distribution, installation and service of... Read More

FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference in New York, New York. Cytek management is scheduled to participate in a fireside chat on Wednesday, September 27 th at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time.... Read More

FREMONT, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, is furthering its mission to advance the next generation of high parameter cell analysis by continuing to have an active presence at key industry events worldwide. The company’s Full Spectrum Profiling™ (FSP™) technology that streamlines workflows, accelerates discoveries and maximizes... Read More

FREMONT, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Seeking to expand the knowledge base surrounding spectral flow cytometry, Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has launched a global roadshow called Cytek Reveal. The roadshow will kick off in South San Francisco on October 5, 2023, and will include stops in San Diego, Boston, Toronto and Cambridge, United Kingdom. Each stop... Read More

FREMONT, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Morgan Stanley 21 st Annual Global Healthcare Conference in New York, New York. Cytek management is scheduled to participate in a fireside chat on Wednesday, September 13 th at 4:15 p.m. Eastern Time / 1:15 p.m. Pacific Time.... Read More

FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and... Read More

FREMONT, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 2023 UBS MedTech, Tools and Genomics Summit in Dana Point, CA. Cytek management is scheduled to participate in the Emerging Life Science Technologies Across Genomics and Proteomics panel on Wednesday, August 16 th at 7:00 a.m.... Read More

FREMONT, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 Total revenue on a non-GAAP constant currency basis was $50.0 million Organic revenue for Cytek’s existing product... Read More

FREMONT, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8 th , 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business... Read More

FREMONT, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 44 th Annual Goldman Sachs Healthcare Conference in Dana Point, CA. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 14 th at 3:20 p.m. Pacific Time / 6:20 p.m. Eastern Time. Interested parties... Read More

FREMONT, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program... Read More

FREMONT, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has shipped its 100 th Cytek Aurora CS system. This milestone is a clear indication of the company’s continuing momentum – and of the scientific community’s desire for... Read More

FREMONT, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31, 2023. First Quarter Highlights Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and 9% increases respectively, over the first quarter of 2022. Organic revenue for Cytek’s existing... Read More

FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9 th , 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments... Read More

FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid Leukemia (AML) Panel. A new single-tube flow panel for the development of AML therapies, this pre-optimized assay allows researchers to quickly and efficiently run AML analysis on any Cytek ® Aurora or Northern Lights™ system equipped... Read More

Full year 2022 revenue increased 28%, or 34% on constant currency basis, compared to prior year Provides full year 2023 revenue guidance of $225 million to $235 million, or growth of 37% to 43% over full year 2022 FREMONT, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the fourth quarter and year ended December 31, 2022.... Read More

SALUGGIA, Italy, and FREMONT, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc . (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million. The decision to sell the FCI business unit... Read More

Sale of assets related to Flow Cytometry & Imaging (FCI) Business Unit Acquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customers Transaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisition Employees associated with commercial, operations, R&D and supporting... Read More

FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 28 th , 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results,... Read More

FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership with leading life science research and clinical diagnostics products company Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). Under the terms of the agreement, Bio-Rad’s exceptionally bright,... Read More

FREMONT, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the following investor conferences: 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on February 14-16 Management will be participating in one-on-one meetings with investors during the event; meetings can... Read More